When Gilead acquired CAR-T leader Kite Pharma, it made a crucial decision not to fully integrate it. This preserved Kite's distinct, individualized therapy operating model, which is fundamentally different from a traditional "off-the-shelf" drug company, proving a key lesson in M&A strategy for novel platforms.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

While acknowledging AI's current impact on productivity (e.g., doubling trial recruitment speed), Gilead views its ultimate transformative potential in supporting complex strategic decisions. This includes using AI to synthesize disparate data (genomic, literature, RWE) to identify the optimal disease indications for a new drug target.

To maintain a competitive edge, BridgeBio only pursues programs that are either "first in class" (a novel treatment where none exists) or "best in class" (a demonstrably superior option, like an oral pill versus a daily injection). This strict strategic filter is the core of their entire R&D pipeline selection process.

Gilead is betting it can overcome the manufacturing and supply chain challenges that have limited J&J's successful Carvykti therapy. While Arcellx's AnitoCell shows similar efficacy, justifying the premium price tag depends on delivering a more reliable and scalable manufacturing process, which remains unproven.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

Gilead has tightened its criteria for advancing projects, demanding a deep mechanistic understanding before committing significant resources. This involves validating the target, understanding its biological impact preclinically, and identifying biomarkers—moving beyond just a promising hypothesis to a de-risked scientific thesis.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.

Gilead's acquisition strategy is not monolithic. It differentiates between acquiring foundational, long-duration platforms (like Kite's CAR-T) that kickstart a whole new area of R&D, and acquiring differentiated assets (like Arcelix's BCMA CAR-T) that strengthen an existing therapeutic area with a potentially transformative molecule.